PMV Pharmaceuticals, Inc. (PMVP) Stock Forecast
PMVP analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 6 analysts
- Price target
- $4.20 average of analyst targets
- Upside to target
- +247.1% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.31
- 52-week range
- $1.02 – $1.80
PMVP analyst ratings
6 analystsNumber of analysts at each rating.
PMVP price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PMVP earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.34 | −$0.41 | −$0.25 | −$0.40 | +15.0% | 3 |
| Current fiscal year (2026) | −$1.28 | −$1.42 | −$1.03 | −$1.48 | +13.3% | 3 |
| Next fiscal year (2027) | −$0.97 | −$1.15 | −$0.61 | −$1.28 | +24.7% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PMVP revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 4 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 5 |
| Next fiscal year (2027) | $5.0M | $0 | $12.5M | 0.0% | 5 |
PMVP EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PMVP revenue: reported and forecast
PMVP EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.35 | −$0.35 | −$0.35 | −$0.39 | −$0.34 | −3.8% | 1 up · 1 down |
| Current fiscal year (2026) | −$1.51 | −$1.51 | −$1.51 | −$1.41 | −$1.28 | −15.3% | 2 up · 0 down |
| Next fiscal year (2027) | −$1.09 | −$1.09 | −$1.09 | −$1.15 | −$0.97 | −11.6% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PMVP earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PMVP beat in 9 of 12.
What analysts expect from PMVP
6 analysts cover PMV Pharmaceuticals; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $4.20, 247.1% above the latest close of $1.21. Analysts expect earnings of −$1.28 per share for 2026, +13.3% from a year earlier. For 2027 the average estimate is −$0.97 per share on revenue of $5.0 million. PMV Pharmaceuticals beat the EPS estimate in 9 of the last 12 quarters.
Related: PMVP income statement, PMVP key metrics, PMVP chart. See the PMVP stock overview for the latest quote and news.
PMVP forecast FAQ
What is PMV Pharmaceuticals's price target?
The average analyst price target for PMV Pharmaceuticals is $4.20, 247.1% above the latest close of $1.21.
Is PMV Pharmaceuticals a buy, hold or sell?
Of 6 analysts covering PMV Pharmaceuticals, 6 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is PMV Pharmaceuticals's EPS forecast?
Analysts forecast −$1.28 per share for 2026 (range −$1.42 to −$1.03); for 2027 the estimate is −$0.97.
When does PMV Pharmaceuticals report earnings?
PMV Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.31.
Does PMV Pharmaceuticals usually beat earnings estimates?
PMV Pharmaceuticals reported EPS at or above the analyst estimate in 9 of the last 12 quarters.